Bicara Therapeutics (BCAX) Research & Development (2023 - 2026)

Bicara Therapeutics has reported Research & Development for 4 years, with the latest figure at $100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 98.48% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $90.9 million (up 81.87% YoY), and the FY2025 full-year result was $125.1 million, up 125.79% from the prior year.
• Research & Development for Q1 2026 stood at $100000.0, down from $33.0 million in the prior quarter.
• The five-year high for Research & Development was $33.0 million in Q3 2025, with the low at $100000.0 in Q1 2026.
• Historically, Research & Development has averaged $15.5 million across 4 years, with a median of $12.0 million in 2024.
• Annual changes were most pronounced in 2025 — Research & Development jumped 181.94% — and 2026, when it plunged 98.48%.
• Bicara Therapeutics' Research & Development stood at $10.5 million in 2023, then increased by 11.46% to $11.7 million in 2024, then jumped by 181.94% to $33.0 million in 2025, then tumbled by 99.7% to $100000.0 in 2026.
• The last three Research & Development figures came in at $100000.0 (Q1 2026), $33.0 million (Q4 2025), and $33.0 million (Q3 2025), per Business Quant data.